Explain When Study Results Are Clinically Meaningful to Patients

It can be hard to decide whether STATISTICALLY significant findings are CLINICALLY significant.

Consider the new COMPASS trial in patients with stable CV disease. It's stirring up controversy...and is a good example.

It suggests that adding rivaroxaban (Xarelto) 2.5 mg BID to low-dose aspirin reduces the risk of a CV event versus aspirin alone...with a p-value less than 0.001.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals